UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.
UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.